Secondary Logo

Journal Logo

Role of sirtuins in kidney disease

Kitada, Munehiro; Kume, Shinji; Koya, Daisuke

Current Opinion in Nephrology and Hypertension: January 2014 - Volume 23 - Issue 1 - p 75–79
doi: 10.1097/01.mnh.0000437330.85675.ac
HORMONES, AUTACOIDS, NEUROTRANSMITTERS AND GROWTH FACTORS: Edited by Mark Cooper and Merlin Thomas
Free

Purpose of review Accumulating evidence indicates the beneficial effects of sirtuins (SIRTs), including SIRT1 and SIRT3, which are NAD+-dependent deacetylases, in age-related diseases such as diabetes, neuron disease, cardiovascular disease and kidney disease.

Recent findings SIRT1 deacetylates many targets, such as transcriptional factors and proteins, and exhibits renoprotection through reduction of fibrosis, antiapoptotic and anti-inflammatory effects and induction of autophagy in renal cells. SIRT1 may also participate in the regulation of blood pressure by sodium handling and by decreasing the responsiveness for angiotensin II. However, SIRT1 may be involved in the progression of cyst formation of renal epithelial cells in autosomal-dominant polycystic kidney disease (ADPKD). SIRT3 protects renal tubular cells against palmitate-induced lipotoxicity through antioxidative and anti-inflammatory effects.

Summary The activation of SIRT1 and SIRT3 may be a novel therapeutic strategy for kidney diseases, but not for ADPKD.

aDivision of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa

bDepartment of Diabetes, Nephrology and Neurology, Shiga University of Medical Science, Shiga, Japan

Correspondence to Daisuke Koya, MD, PhD, Division of Diabetology and Endocrinology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-Gun, Ishikawa 920-0293, Japan. Tel: +81 76 286 2211; e-mail: koya0516@kanazawa-med.ac.jp

Back to Top | Article Outline

INTRODUCTION

Ageing is a universal process that affects all organs. Age-related disruptions in cellular homeostasis result in declines in organ functions and in the responsiveness to physiological stress. Renal function gradually declines with age in most healthy individuals [1], and the amount of glomerular, vascular and interstitial scarring in the renal tissue of healthy adults increases with age [2]. Ageing is a risk factor for end-stage renal failure [3]; therefore, elucidating the process of renal ageing may support better treatments for both chronic kidney disease (CKD) and acute kidney injury (AKI).

Calorie restriction without malnutrition promotes longevity and slows ageing [4]. One possible mechanism by which calorie restriction exerts beneficial effects involves the actions of sirtuins (SIRTs), especially SIRT1. The activation of SIRT1, which is an NAD+-dependent deacetylase, may lead to the induction of gene silencing, reduction of apoptosis and inflammation, enhanced mitochondrial biogenesis, regulation of glucose/lipid metabolism, induction of autophagy and adaptation to cellular stress, by the deacetylation of histone and more than a dozen nonhistone proteins, including transcription factors and transcriptional coregulatory proteins [5]. SIRT3, which is an NAD+-dependent deacetylase in mitochondria that is induced by calorie restriction, also regulates the antioxidative defense system, metabolism and longevity [5,6]. Therefore, SIRT1 and SIRT3 may improve or retard age-related diseases, including diabetes, cardiovascular diseases, neurodegenerative disorders and kidney diseases. Recent studies show that SIRT1 activation associated with calorie restriction retards the normal ageing process in the kidney, and SIRT1 and SIRT3 act as renoprotective molecules for various kidney disorders in animal models. In this review, we focus on the role of SIRT1 and SIRT3 in the kidneys and discuss the potential of sirtuin-based therapeutics against kidney diseases.

Box 1

Box 1

Back to Top | Article Outline

INTESRSTITIAL FIBROSIS, TUBULAR CELL APOPTOSIS AND SIRT1 IN THE KIDNEY

Tubulointerstitial fibrosis is considered to be a central event in the progression of CKD independent of cause. Even in glomerulopathies, tubulointerstitial fibrosis correlates better than glomerular injury with the evolution and prognosis of the kidney disease [7]. The epithelial-to-mesenchymal transition (EMT) plays a pivotal role in the pathogenesis of the development of organ fibrosis, including renal fibrosis [8]. Simic et al.[9▪▪] reported that SIRT1 can reduce EMT in kidney fibrosis by deacetylating Smad4 and repressing the effect of transforming growth factor-β (TGF-β) signalling on matrix metalloproteinase 7 (MMP7), a Smad4 target gene. They found that the reduction of MMP7 expression decreases the amount of cleaved E-cadherin, and β-catenin remains bound to E-cadherin at the cell–cell junctions.

Yuan et al.[10] demonstrated that aldosterone reduced peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) activity by downregulating its expression but increasing its acetylation and inducing mitochondrial dysfunction in cultured proximal tubular cells. Overexpression of PGC-1α could prevent aldosterone-induced mitochondrial dysfunction and EMT. SIRT1 activation by resveratrol results in the deacetylation of PGC-1α and restores mitochondrial dysfunction and EMT. Li et al.[11] reported that SIRT1 activation by resveratrol inhibited the acetylation of Smad3, resulting in reduction of TGF-β1 induced collagen IV and fibronectin expression in a unilateral ureteral obstruction (UUO) animal model and in cultured cells (rat fibroblasts: NRK49F; rat proximal tubular cells: NRK52E).

Renal tubular cell apoptosis is involved in the progression of kidney injury. He et al.[12] reported that SIRT1 was abundantly expressed in mouse medullary interstitial cells and increased cellular resistance to oxidative stress. Decreased SIRT1 was associated with increased apoptosis and fibrosis after UUO in Sirt1 (+/−) mice, while SIRT1 activation in wild-type mice reduced apoptotic and fibrotic changes in the UUO model. SIRT1 deficiency decreases the induction of cyclooxygenase 2 (COX2) in medullary interstitial cells under oxidative stress, and exogenous prostaglandin E2 reduces apoptosis in oxidatively stressed SIRT1-deficient cells. These findings indicate the protective function of SIRT1 and identify COX2 as a target of SIRT1.

Hasegawa et al.[13] found that SIRT1 protects against oxidative stress induced apoptosis by inducing catalase via deacetylation of FOXO3 in cultured proximal tubular cells. Moreover, they reported that renal proximal tubular cell-specific SIRT1 transgenic mice exhibited resistance to cisplatin-induced renal tubular cell injuries, such as apoptosis, by maintaining peroxisome number and function, concomitant upregulation of catalase and elimination of renal oxidative stress [14]. Another study [15] showed that SIRT1 activation by resveratrol reduced cisplatin-induced proximal tubular cell apoptosis through deacetylation of p53.

Back to Top | Article Outline

INFLAMMATION AND SIRTUINS IN THE KIDNEY

The inflammatory process is a pivotal mechanism for the initiation and progression of kidney diseases [16]. Therefore, controlling the inflammatory process might be a potential therapeutic target. The nuclear factor-κB (NF-κB) signalling pathway plays a central role in the regulation of inflammatory processes [17]. SIRT1 may act as a negative regulator of NF-κB activity by deacetylating the p65 subunit, which may cause anti-inflammatory effects [18].

We found that SIRT1 protein expression significantly decreased and the amount of acetylated NF-κB p65 and the inflammation process increased in the kidneys of Wistar fatty diabetic rats (WFRs) compared with Wistar lean nondiabetic rats (WLRs). The increased levels of acetylated NF-κB and inflammation in WFRs were decreased by calorie restriction, which was consistent with the restoration of SIRT1 protein expression in the kidney. Therefore, renal inflammation is induced by increased levels of acetylated NF-κB p65 as a result of the reduced SIRT1 protein expression, while calorie restriction exerts anti-inflammatory effects by restoring SIRT1 expression in the kidneys of WFRs [19]. In addition, Jung et al.[20] reported that the administration of cisplatin in renal proximal tubular cells (HK-2 cells) reduced SIRT1 expression and was associated with increased levels of acetylated NF-κB p65, and that overexpression of SIRT1 ameliorated cisplatin-induced hyperacetylation of NF-κB p65 and cell injury.

Free fatty acid mediated renal lipotoxicity is associated with the progression of tubulointerstitial inflammation in proteinuric kidney disease [21]. Koyama et al.[22] demonstrated that SIRT3 exhibits antioxidant and anti-inflammatory effects under conditions of palmitate-induced lipotoxicity by enhancing the mitochondrial oxidative capacity and antioxidant defenses in proximal tubular cells.

Back to Top | Article Outline

ROLE OF SIRT1 IN GLOMERULAR CELLS

Apoptosis is a distinct form of cell death observed under various physiological and pathological conditions [23]. Glomerular cells, including mesangial cells and podocytes, exhibit enhanced apoptosis in human and experimental kidney diseases. Therefore, suppressing glomerular cell apoptosis may help prevent various kidney diseases.

Podocytes serve as a crucial component of the glomerular filtration barrier. Podocyte loss induced by apoptosis is observed in several kidney diseases and is involved in the pathophysiology of kidney injury. Podocyte apoptosis can be induced by several factors, such as aldosterone and advanced glycation end products (AGEs). Yuan et al.[24▪] reported that the SIRT1/PGC-1α axis in mitochondria ameliorates aldosterone-induced podocyte injuries. They found that aldosterone suppressed SIRT1 and PGC-1α activation in cultured podocytes, which resulted in increased podocyte apoptosis, the loss of slit diaphragm proteins including nephrin and podocin, and mitochondrial dysfunction. SIRT1 activation protected against aldosterone-induced podocyte injuries with mitochondrial dysfunction by inhibiting both apoptosis and the loss of slit diaphragm proteins through deacetylation and activation of PGC-1α. Chuang et al.[25] also found that AGE-modified bovine serum albumin (AGE-BSA) increases FOXO4 acetylation and suppresses the expression of the SIRT1 protein in glomerular podocytes of db/db diabetic mice and diabetic patients. Acetylated FOXO4 promotes the expression of the pro-apoptosis gene Bcl2l11 (also known as Bim) and leads to podocyte apoptosis [25].

SIRT1 decreases mesangial cell apoptosis induced by oxidative stress by reducing p53 activity [26] and attenuates TGF-β induced apoptotic signalling mediated by the effector molecule Smad7 [27]. SIRT1-dependent deacetylation of Smad7 also enhances the ubiquitin-dependent proteasomal degradation of Smad7 by Smad ubiquitination regulatory factor1 (Smurf1).

Back to Top | Article Outline

AUTOPHAGY AND SIRT1 IN THE KIDNEY

Autophagy is a lysosomal degradation pathway that plays a crucial role in removing protein aggregates and damaged organelles such as mitochondria to maintain intracellular homeostasis and promote cellular health under various stress conditions, including hypoxia [28,29]. Dysfunction of autophagy is involved in the pathogenesis of age-related disease, including kidney disease [30]. SIRT1 can positively regulate autophagy by deacetylating essential autophagic factors such as autophagy-related gene (Atg)5, Atg7 and light chain3 (LC3) [31]. Furthermore, SIRT1 deacetylates the transcription factor FOXO3a, which leads to enhanced expression of proautophagic BCL2/adenovirus E1V 19-kDa interacting protein 3 (Bnip3) [32].

We have shown that hypoxia-induced autophagy activity declines with age in mice, which leads to the accumulation of damaged mitochondria and mitochondrial oxidative stress in the kidneys [32]. Interestingly, long-term calorie restriction restores autophagy activity, even in aged kidneys. We found that SIRT1-mediated autophagy is essential in the calorie restriction mediated protection of aged kidneys. Bnip3 expression is essential for inducing autophagy under hypoxic conditions and is positively regulated by FOXO3a; however, regulation is altered in aged kidneys. Calorie restriction mediated SIRT1 activation deacetylates and activates FOXO3a transcriptional activity and subsequent Bnip3-mediated autophagy, even in aged kidneys. Furthermore, the kidneys of Sirt1(+/−) mice exhibit lower autophagy activity and decreased Bnip3 expression and are thereby resistant to calorie restriction mediated antiageing effects. These findings suggest that SIRT1 is essential for calorie restriction mediated renoprotection, which is induced by removing the damaged mitochondria under hypoxic conditions via Bnip3-mediated autophagy. In addition, we noted mitochondrial morphological damages in the proximal tubular cells and p62/Sqstm1 accumulation in the kidneys of diabetic WFRs. p62/Sqstm1 binds to ubiquitylated substrates and LC3 on autophagosomes, and is itself degraded by autophagy [29]; therefore, the accumulation of p62/Sqstm1 indicates the impairment of autophagy, resulting in mitochondrial damage. Because SIRT1 is a positive regulator of autophagy, decreased SIRT1 expression in diabetic kidneys may lead to dysregulation of autophagy. Calorie restriction improves the function of autophagy, which results in normalization of mitochondrial morphological changes and p62/Sqstm1 accumulation accompanied by the restoration of SIRT1 expression [19].

Back to Top | Article Outline

ROLE OF SIRTUINS IN Na+ HANDLING AND BLOOD PRESSURE REGULATION

Angiotensin II (Ang II) plays important roles in the pathogenesis of CKD and hypertension. Ang II is a mediator of glomerular haemodynamic adaptation and injury, and exhibits pro-inflammatory actions, which lead to upregulation of chemokines, adhesion molecules and other fibrogenic growth factors, and decline in renal function. Most of the traditional cardiovascular effects of Ang II, such as vasoconstriction and sodium retention, are mediated by angiotensin type 1 receptor subtype (AT1R). SIRT1 may negatively regulate AT1R expression. Miyazaki et al.[33] reported that overexpression of SIRT1 or treatment with resveratrol suppresses AT1R expression by reducing the binding of Sp1 to the AT1R promoter in cultured smooth muscle cells. Resveratrol also suppresses AT1R expression in the aorta and improves Ang II-induced hypertension in mice. Interestingly, the lifespans of Atr1 (−/−) mice are extended compared with wild-type mice, and the expression of SIRT3, but not SIRT1, is significantly increased in the kidneys of Atr1 (−/−) mice [34]. However, the role of SIRT3 in renal ageing remains unclear.

Aldosterone increases renal tubular Na+ absorption by increasing the transcription of the epithelial Na+ channel α-subunit (α-ENaC) in the apical membranes of collecting-duct principal cells. The increased transcription contributes to the pathogenesis of hypertension. SIRT1 represses the expression of α-ENaC in mIMCD3 cells independent of its deacetylase activity [35]. SIRT1 interacts with disruptor of telomeric silencing (Dot)-1, a histone H3K79 methyltransferase, which results in H3K79 hypermethylation in chromatin along the α-ENaC promoter and represses α-ENaC transcription. Treatment with aldosterone decreases SIRT1 mRNA expression, whereas SIRT1 inhibits aldosterone-induced α-ENaC promoter activity independent of mineralocorticoid receptor signalling [35].

Back to Top | Article Outline

SIRT1 AND AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE

Autosomal-dominant polycystic kidney disease (ADPKD) is caused by mutations in Pkd1 or Pkd2 and is characterized by the development of multiple bilateral renal cysts that replace the normal kidney. Zhou et al.[36▪] reported that SIRT1 is involved in the pathogenesis of ADPKD. Increased SIRT1 expression in Pkd1 mutant renal tubular cells regulates cystic epithelial cell proliferation through deacetylation and phosphorylation of Rb and regulates cystic epithelial cell death through deacetylation of p53 [36▪]. These findings suggest that suppression of SIRT1 using a SIRT1 inhibitor, such as nicotinamide, may be useful to delay cyst formation in ADPKD.

Back to Top | Article Outline

CONCLUSION

SIRT1 exerts renal protective effects by reducing fibrosis, inhibiting apoptosis and inflammation, inducing autophagy and regulating blood pressure (Fig. 1). Therefore, SIRT1 may be a novel therapeutic target for kidney disease. However, in ADPKD, SIRT1 is involved in the progression of cyst formation (Fig. 1). SIRT3 may have important roles in renoprotection (Fig. 1); however, further investigation into the targets and functions of SIRT3 will aid the development of new strategies for protection against kidney disease.

FIGURE 1

FIGURE 1

Back to Top | Article Outline

Acknowledgements

This work was supported by a grant from a Grant-in-Aid for Scientific Research (C) (24591218) and a Grant for Promoted Research from Kanazawa Medical University (S2013-2) to M. Kitada, a Grant-in-Aid for Scientific Research (B) (25282028), a Grant-in-Aid for Challenging Exploratory Research (25670414) and the 4th Annual Research Award Grant of the Japanese Society of Anti-Aging Medicine to D. Koya.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1–12.
2. Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 2010; 152:561–567.
3. Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169:342–350.
4. Fontana L, Partridge L, Longo VD. Extending healthy life span: from yeast to humans. Science 2010; 328:321–326.
5. Guarente L, Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med 2011; 364:2235–2244.
6. Someya S, Yu W, Hallows WC, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010; 143:802–812.
7. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20:1–17.
8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420–1428.
9▪▪. Simic P, Williams EO, Bell EL, et al. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 2013; 3:1175–1186.

This article demonstrates that SIRT1 supresses TGF-β induced EMT in the kidney by deacetylating Smad4, and reduces renal fibrosis.

10. Yuan Y, Chen Y, Zhang P, et al. Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic Biol Med 2012; 53:30–43.
11. Li J, Qu X, Ricardo SD, et al. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 2010; 177:1065–1071.
12. He W, Wang Y, Zhang MZ, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 2010; 120:1056–1068.
13. Hasegawa K, Wakino S, Yoshioka K, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 2008; 372:51–56.
14. Hasegawa K, Wakino S, Yoshioka K, et al. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem 2010; 285:13045–13056.
15. Kim DH, Jung YJ, Lee JE, et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 2011; 301:F427–F435.
16. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7:327–340.
17. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132:344–462.
18. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369–2380.
19. Kitada M, Takeda A, Nagai T, et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011; 2011:908185.
20. Jung YJ, Lee JE, Lee AS, et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun 2012; 419:206–210.
21. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 1993; 13:385–398.
22. Koyama T, Kume S, Koya D, et al. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Biol Med 2011; 51:1258–1267.
23. Hattori T, Shindo S, Kawamura H. Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model. Nephron 1998; 79:186–191.
24▪. Yuan Y, Huang S, Wang W, et al. Activation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int 2012; 82:771–789.

This article shows that SIRT1 activation protected against aldosterone-induced podocyte injuries with mitochondrial dysfunction through deacetylation and activation of PGC-1α.

25. Chuang PY, Dai Y, Liu R, et al. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011; 6:e23566.
26. Kume S, Haneda M, Kanasaki K, et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006; 40:2175–2182.
27. Kume S, Haneda M, Kanasaki K, et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007; 282:151–158.
28. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069–1075.
29. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280–293.
30. Tanaka Y, Kume S, Kitada M, et al. Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res 2012; 2012:628978.
31. Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013; 124:153–164.
32. Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010; 120:1043–1055.
33. Miyazaki R, Ichiki T, Hashimoto T, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1263–1269.
34. Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119:524–530.
35. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007; 282:34356–34364.
36▪. Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest 2013; 123:3084–3098.
Keywords:

antiapoptosis; antifibrosis; anti-inflammation; autophagy; SIRT1; SIRT3

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.